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INTRODUCTION 14
Erythropoiesis is the process of red blood cell production; defects in this process lead to anemia and 15 thus insufficient oxygen delivery to tissues and subsequent organ failure. Therefore, the formation of 16 red blood cells has to be tightly controlled during embryonic development and homeostasis in the 17 adult. 18 KLF1 (previously known as EKLF) is a well-characterized, erythroid-specific transcription factor and 19 one of the critical regulators of red blood cell maturation. KLF1 acts mainly as an activator and its 20 target genes are involved in multiple processes of erythroid differentiation, including cell cycle 21 regulation (1, 2), hemoglobin metabolism (3), and expression of membrane skeleton proteins (4, 5). 22
The importance of KLF1 is illustrated by Klf1 knockout embryos which die around E14 due to the lack 23 of functional erythrocytes (6, 7). In contrast, heterozygous Klf1+/− mice survive into adulthood, 24
showing that haploinsufficiency for KLF1 does not have a severe phenotype (8) . KLF1 has a 25 N-terminal transactivation domain and a C-terminal DNA binding domain, composed of three zinc 26 fingers. They mediate specific DNA binding to 5'-CACCC-3' motifs (9). Variants in human KLF1 are 27 found across the entire gene. The majority are missense variants in the three zinc fingers, which 28 presumably alter the DNA binding/sequence recognition properties of KLF1. Mutations in KLF1 are 29 associated with different phenotypes in humans (10), such as In(Lu) blood group (11), hereditary 30 persistence of fetal hemoglobin (HPFH) (12), zinc protoporphyria (13), increased HbA2 (14), and 31 congenital dyserythropoietic anemia (CDA) type IV (15). 32
The Neonatal anemia (Nan) mouse is an ethylnitrosourea (ENU)-induced semi-dominant hemolytic 33 anemia model first described in 1983 by Mary Lyon (16), who positioned the variant on chromosome 8 34 (17). In 2010, Klf1 was identified as the gene responsible for this phenotype, due to a single point 35 mutation in the second zinc finger (p.E339D) (18, 19) . While Klf1 Nan homozygous mice die around 36 E10, KLF1 Nan heterozygous mice survive into adulthood displaying life-long hemolytic anemia. This 37 indicates that the Nan variant affects the function of wildtype KLF1 protein, as this phenotype does not 38 occur in Klf1 haplo-insufficient mice (6-8, 18, 19) . Indeed, the DNA binding properties of Nan KLF1 39 may be altered due to steric clash between the carboxyl group of p.339D and the methyl group of 40 thymidine, resulting in the deregulation of a subset of target genes (19), although alternative models 41 have been proposed (18) . 42
Until now, research has focused on the effects of the Nan variant in adult mice (18) (19) (20) . Given that 43 KLF1 expression begins around E7.5 (21), it is of interest to investigate the impact of aberrant KLF1 44 activity during development. Here we investigated erythropoiesis during different stages of fetal 45 development and observed impaired red blood cell maturation at E12.5, as assessed by flow 46 cytometry analysis of the CD71 and Ter119 markers. Expression profiling of E12.5 fetal liver cells 47 revealed 782 deregulated genes in Nan mutant samples including a host of known KLF1 targets such 48 5 as Dematin and E2F2 (1, 4, 22) . Intriguingly, the nuclear exportin XPO7, which has recently been 49 implicated in nuclear condensation and enucleation during erythroid maturation (23), was one of the 50 deregulated genes. XPO7 expression was significantly downregulated in the presence of the Nan 51 variant erythroid progenitors, contributing to increased nuclear size. This partially explains the 52 erythroid defects observed in Nan erythroid cells and provides a novel link between KLF1 and nuclear 53 condensation. 54 55 6
MATERIAL AND METHODS 56
Mice 57
All animal studies were approved by the Erasmus MC Animal Ethics Committee. The mouse strains 58 used were Klf1 Nan mutant (16) and Klf1 knockout (6). Genotyping was performed by PCR using DNA 59 isolated from toe biopsies. For Nan genotyping, the PCR product was digested with DpnII. Embryos 60 were collected at E12.5, E13.5, E14.5 and E18.5; tail DNA was used for genotyping. Primer 61 sequences are detailed in Supplementary Materials and Methods. 62 63
Blood analysis 64
Peripheral blood was collected from the mandibular vein of adult mice, and standard blood parameters 65
were measured with an automated hematologic analyzer (Scil Vet ABC, Viernheim, Germany). 66 67 Cell culture and transduction 68 I/11 erythroid progenitors and primary mouse fetal liver cells were cultured as described (24). To 69 induce differentiation of I/11 cells we used StemPRO-34 SFM (10639-011, life technologies) 70
supplemented with 500 μg/mL iron-saturated transferrin (Scipac) and Epo (Janssen-Cilag, 10 U/mL). 71
Lentiviral shRNAs targeting XPO7 were obtained from the Sigma MISSION shRNA library. The clones 72 used are detailed in Supplementary Materials and Methods. 73
74

RNA isolation and RT-qPCR analyses 75
RNA was extracted using TRI reagent (Sigma-Aldrich). To synthesize cDNA, 2 μg of RNA were used 76 together with oligo dT (Invitrogen), RNase OUT (Invitrogen), and SuperScript reverse transciptase II 77 (Invitrogen) in a total volume of 20 μL for 1 hour at 42 0 C. 0.2 μL of cDNA was used for amplification by 78 RT-qPCR. Other experimental details and primer sequences are detailed in Supplementary Materials 79 and Methods. 80 81
Protein extraction and western blotting 82
Total protein extracts from mouse fetal liver cells were prepared according to (25). To visualize protein 83 expression, cell lysates of ~3x10 6 cells were loaded on 10% SDS-polyacrylamide gels for 84 electrophoresis. The gels were transferred to nitrocellulose blotting membrane 0.45 μm (10600002, 85 GE Healthcare) and probed with specific antibodies. Membranes were stained for Tubulin (T5168, 86
Sigma-Aldrich) as loading control, and for XPO7 (sc390025, Santa Cruz). 
RNA-sequencing and analysis 92
RNA-seq was performed according to manufacturer's instructions (Illumina; San Diego, CA, USA), as 93 described(26). The sequenced reads were mapped against the mouse genome build mm10 using 94 4C-seq experiments were carried out as described (29, 30). Briefly, 4C-seq template was prepared 100 from E13.5 fetal liver or fetal brain cells. In total, between 1 and 8 million cells were used for analysis. 101 
Characterization of Nan fetal liver cells 112
The effect of the KLF1 Nan variant has been studied in adult mice (18-20), but data on its effect during 113 gestation is limited. Hence, to study this variant during embryonic development, we used a Nan mouse 114 model carrying one mutant allele (Nan/+, from now on called Nan). At E12.5, E14.5, and E18.5, Nan 115 embryos were paler than wildtype littermates, indicating anemia, but otherwise looked phenotypically 116 normal. Flow cytometry analysis of E12.5, E14.5, and E18.5 fetal liver cells used the Kit, CD71, 117
Ter119 and CD44 markers to trace red blood cell differentiation. A severe downregulation in 118 expression of the Ter119 marker was observed at all three stages ( Figure 1A,B ). The CD71/Ter119 119 double-positive population was significantly decreased in the Nan samples, while the CD71 120 single-positive population showed an increase. No significant differences were observed for Kit and 121 CD44 in the Nan variant (Supplementary Figure 1A,B ). In addition, similar results were obtained when 122 assaying embryonic blood, with Ter119 being highly downregulated ( Figure 1C ,D). These results 123 indicate that Nan embryos display delayed erythroid maturation compared to wildtype controls. This is 124 in line with the observation that a higher percentage of cells is positive for CD71 in adult blood 125 ( Supplementary Figure 2A ,B), indicative of higher percentage of circulating reticulocytes (19) . 126
Consistent with this notion, analysis of standard blood parameters revealed a significant increase in 127 red cell distribution width (RDW) in the Nan mice (Supplementary Figure 2C ). Furthermore, we 128 observed minor, yet significant, decreases in RBC (red blood cell), HGB (total hemoglobin), HCT 129
(hematocrit), MCH (Mean Corpuscular Hemoglobin), MCHC (Mean Corpuscular Hemoglobin 130
Concentration) values. Interestingly, when comparing Nan E14.5 fetal liver cytospins to wildtype 131 controls, we observed a marked increase in the average size of the erythroid cells and their nuclei 132 ( Figure 1E ). Taken together, these data show that erythroid maturation is impaired in Nan animals. 133 134
Identification of deregulated genes in E12.5 Nan fetal livers 135
In order to identify genes that are affected by the Nan variant, a genome-wide RNA-seq was 136 performed on samples derived from E12.5 Nan and wildtype fetal livers (N=6 each), as at this stage 137 the fetal liver is mainly composed of erythroid cells. 782 genes appeared to be deregulated in the Nan 138 mutants (false discovery rate [FDR] <0.01, absolute fold change equal or greater than 1.5), of which 139 437 were upregulated and 345 downregulated ( Figure 2A,B and Supplementary Table 1 ). Strikingly, 140 even though KLF1 has been mainly described as a transcriptional activator, the majority of the 141 deregulated genes displayed increased activation in the Nan erythroid cells. We postulate that this 142 might be due to secondary effects of KLF1 on other transcriptional regulators and/or aberrant activity 143 of KLF1 Nan. To validate the data, we checked the expression of Epb4.9 and E2f2, genes known to 144 be down-regulated in Nan erythroid cells (19) ( Figure 2D , left panel and Supplementary Figure 3) . 145 9 Indeed, a significant decreased expression of the transcripts of these two genes was detected in Nan 146 fetal livers. Moreover a significant 2-fold down-regulation of BCL11A, a known target of KLF1 (12, 31), 147 was observed indicating that the KLF1 Nan variant affects its expression ( Figure 2D The expression of the Xpo7 gene, encoding a nuclear exportin, was prominently downregulated in 158 Nan E12.5 fetal livers (~4-fold decrease; Figure 2A ). This raised our interest since XPO7 was recently 159 implicated in terminal erythroid differentiation, as a protein involved in enucleation (23). To corroborate 160 the RNA-seq data, XPO7 expression in Nan E14.5 fetal livers was reduced by approximately 90% in 161
the Nan samples as determined by RT-qPCR ( Figure 3A ). Transcripts using the canonical first exon 162
were barely detectable in all samples (not shown). Importantly, XPO7 protein levels were also reduced 163
in Nan fetal liver cells ( Figure 3B ). To investigate whether XPO7 expression is dependent on KLF1, 164 XPO7 mRNA and protein levels were measured in Klf1 null erythroid cells. In E13.5 Klf1 null fetal 165 livers (6) expression of XPO7 mRNA and protein is significantly reduced ( Figure 3C ,D). Remarkably, 166 downregulation of XPO7 was also observed in Klf1 wt/ko fetal livers, although to a lesser extent than 167 observed in Klf1 null fetal livers ( Figure 3C ,3D). Thus, similar to BCL11A (12, 31), activation of XPO7 168 by KLF1 is dose-dependent. In agreement with the notion that KLF1 is a direct activator of the Xpo7 169 gene, KLF1 binds to the canonical promoter and first intron of the Xpo7 gene in mouse (32) and 170 human (33) erythroid cells ( Supplementary Figure 4) . 171 172 10
The chromatin conformation of the Xpo7 locus is not affected in Nan erythroid cells 174
Since KLF1 is required to form an active chromatin hub in the β-globin locus (34), 4C-seq experiments 175 were performed on the Xpo7 locus in E13.5 wildtype fetal livers and fetal brains and Nan mouse fetal 176 livers ( Figure 4A ). The canonical promoter of Xpo7 was used as viewpoint to investigate potential 177 changes in chromatin conformation ( Figure 4B ). Interestingly, a loop was identified between the 178 canonical promoter of Xpo7 (situated at the beginning of exon 1a) and the exon that produces the 179 erythroid-specific form of Xpo7 (exon 1b), indicating that these two regions are in spatial proximity in 180 erythroid cells ( Figure 4B ), whereas this loop has lower contact frequencies in fetal brain. However, 181 few local changes in the chromatin conformation were found between wildtype and Nan samples 182 ( Figure 4B ). The experiment was repeated using the erythroid-specific promoter as view point. This 183 confirmed the results obtained with the canonical promoter as viewpoint. ( Figure 4C ). We suggest that Hoechst-negative populations and prepared cytospins. This showed all the Hoechst-negative cells 195 identified by flow cytometry to indeed be enucleated ( Figure 5C ). In addition, assessing enucleation 196 levels of mouse fetal liver cells cultured in proliferative medium and in differentiation medium from 197 embryos at E12.5 and E14.5 by flow cytometry, similar ratios of nucleated versus enucleated cells 198 were found in control and Nan samples (Supplementary Figure 5A,B ). Nevertheless, a striking 199 increase in the percentage of large cells in the fetal livers of the Nan embryos was observed. 200
Quantification of cell size using flow cytometry revealed a significant increase in average cell size at 201 E12.5, E14.5 and E18.5 in the Nan samples ( Figure 5D ). In line with this finding the nuclear area of 202 the Nan fetal liver cells was significantly increased when compared to control fetal liver cells in 203 cytospin slides stained with the nuclear dye Hoechst 33342 ( Figure 5E ). These data are consistent 204 with the notion that XPO7 is involved in nuclear condensation, a process that precedes enucleation. 205
However, despite the impaired nuclear condensation, the cells still are still able to undergo enucleation 206 as we observed similar ratios of nucleated versus enucleated cells in control and Nan fetal liver cells. 207 208 XPO7 knock down in I/11 cells mimics the phenotype of Nan cells 209
The role of XPO7 in erythroid differentiation was further analyzed by knocking down XPO7 in the 210 factor-dependent immortalized mouse erythroid cell line I/11 (35). Using three different shRNAs, an 211 efficiency of ~70% knockdown was reached as shown by Western blot ( Figure 6A ). Before 212 differentiation a minor difference in expression of the surface markers CD71 and Ter119 and no 213 difference in cell size between the control and the knockdown cells was observed (data not shown). In 214 contrast, upon transfer to differentiation medium, the maturation of XPO7 knockdown cells was 215 impaired, as shown by CD71 and Ter119 flow cytometry analysis ( Figure 6B) , and the average cell 216 size was increased ( Figure 6C ). In addition, using an ImageStream flow cytometer showed the mean 217 and median size of the nuclear area to be increased upon XPO7 knockdown when the cells were 218 cultured under differentiation conditions. This is consistent with the notion that XPO7 is required for 219 nuclear condensation during terminal erythroid differentiation. Collectively, these findings indicate that 220 XPO7 is partially responsible for the phenotype of Nan mice, establish that the Xpo7 gene is a novel 221 erythroid target gene of KLF1, and that nuclear condensation is a process previously unrecognized to 222 be regulated by KLF1. 223
224
DISCUSSION 225
Erythropoiesis is a complex process that involves many players whose coordinated activity ensures 226 the production of functional red blood cells. One of these players is KLF1, a transcription factor with 227 multiple roles during terminal erythroid differentiation. Firstly, it is essential for globin regulation, in 228 particular for direct activation of β-globin (6, 7). In addition, it acts as a master regulator of genes 229 activated during differentiation of red blood cells, such as membrane proteins, heme synthesis 230 enzymes and cell cycle regulators (2, 4, 22). Hence, it comes as no surprise that Klf1 knockout 231 embryos die due to severe anemia, and that the phenotype is not rescued by exogenous expression 232 of a β-like globin gene (36). Accordingly, KLF1 variants can lead to diverse phenotypes in humans 233 (10). One example is a missense variant in the second zinc finger of human KLF1 (p.E325K) that 234 causes CDA type IV (15). This variant is believed to affect binding of KLF1 to its target genes thereby In this paper we present our findings on the effects of the Nan variant on definitive fetal erythropoiesis 240 and show that erythroid maturation is impaired in Nan fetal livers at E12.5, E14.5 and E18.5. We 241 identified 782 differentially expressed genes in Nan versus control E12.5 fetal livers. In agreement with 242 a previous report on erythropoiesis in adult Nan mice (19), the expression of globin genes is altered in 243 Nan fetal livers. In particular, the upregulation of embryonic βh1 globin can be explained by the 244 significantly lower expression of BCL11A in Nan embryos, which normally suppresses βh1 expression 245 (37). Xpo7, encoding a nuclear exportin, was one of the most significantly downregulated genes. It 246 caught our attention since a recent paper described that Xpo7 is required for nuclear condensation 247 and enucleation during terminal erythroid differentiation in vitro (23). In addition, the observation that 248 XPO7 expression was also reduced in Klf1 knockout fetal livers indicated that the Xpo7 gene might be 249 a direct target of KLF1. Supporting this notion, data mining of ChIP-seq results revealed that KLF1 250 binds to the Xpo7 locus in mouse (32) and human (33) erythroid cells. Collectively, these data 251 suggested that, similar to the β-globin locus (34), KLF1 might have a role in the spatial organization of 252 the Xpo7 locus. 4C-seq analysis of the Xpo7 locus demonstrated that it adopts a different 253 conformation in fetal liver cells compared to fetal brain cells. The presence of the Nan variant doesn't 254 appear to mediate any major changes in the chromatin conformation of the Xpo7 locus. We note that 255 the promoter of the Xpo7 gene contains so-called 'category II' KLF1 binding sites(19) which are 256 recognized by wildtype KLF1 only. The presence of such 'category II' sites is a hallmark of 257 downregulated genes in Nan erythroid cells. This suggests that in Nan cells wildtype KLF1 is still able 258 to bind to the Xpo7 promoter and organize the erythroid-specific 3D conformation of the locus, but is 259 13 unable to activate transcription efficiently. An interesting observation is the presence of a loop 260 between the promoter of the canonical Xpo7 promoter (in front of exon 1a) and the erythroid-specific 261 promoter (in front of exon 1b), which is absent in the fetal brain control. This loop is likely the 262 consequence of recruitment of the two promoters to the same transcription factory (38). Previous work 263 has shown that XPO7 knockdown in cultured mouse fetal liver cells impairs chromatin condensation 264 and enucleation during terminal erythroid differentiation (23). Although in Nan mice enucleation still 265 occurs, the reduced XPO7 expression due to the Nan variant impairs chromatin condensation during 266 terminal erythroid differentiation. We propose that this contributes to the maturation defects of Nan 267 Lastly, a protein with a role similar to that of XPO7 may substitute for it, thus enabling enucleation. We 278 favour a scenario in which chromatin condensation is crucial for enucleation (39-41), with XPO7 as an 279 important effector. It is not clear whether enucleation can happen before nuclear condensation is 280 completed. Our study suggests that impaired nuclear condensation contributes to the erythroid 281 maturation defects observed in the Nan mice. 282
Understanding the role of KLF1 during erythroid maturation and the enucleation process has clinical 283 significance for the production of red blood cells in vitro for transfusion purposes. In recent years, 284 many efforts have been made to produce erythrocytes in vitro starting from hematopoietic stem cells, 285 embryonic stem cells or induced pluripotent stem cells (42-44). Efficient enucleation is one of several 286 challenges that have to be overcome in order to produce sufficient numbers of fully functional 287 erythrocytes in vitro. More in depth knowledge of this process might guide the development of 288 improved strategies to achieve this goal. 
